Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30638498 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NPC1RAB9AMEN1NFKB1 | |
| SCHEMBL10091207 | 0.98 | L3MBTL1 (0.54) | L3MBTL1NPC1RAB9AMEN1NFKB1 | |
| SCHEMBL12856701 | 0.87 | PTPRC (0.56) | L3MBTL1NPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL23416842 | 0.84 | PTPRC (0.47) | L3MBTL1NPC1RAB9AMEN1NFKB1 | |
| SCHEMBL1047349 | 0.82 | MEN1 (0.45) | L3MBTL1NPC1RAB9AMEN1NFKB1 | |
| SCHEMBL8036362 | 0.82 | LMNA (0.50) | NPC1RAB9AMEN1NFKB1NFKB2 | |
| SCHEMBL17550730 | 0.80 | MEN1 (0.44) | L3MBTL1NPC1RAB9AMEN1NFKB1 | |
| SCHEMBL10091240 | 0.80 | MEN1 (0.44) | L3MBTL1NPC1RAB9AMEN1NFKB1 | |
| SCHEMBL2140802 | 0.80 | ALDH1A1 (0.50) | L3MBTL1NPC1RAB9AMEN1NFKB1 | |
| SCHEMBL533630 | 0.80 | PTGS2 (0.50) | L3MBTL1NPSR1ALDH1A1MAPTPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| WO-2024126322-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024013276-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024013275-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2024-01-18 | — | — | WO | disclosed |
| EP-3935129-B1 | LIGANDS FOR NANO-SIZED MATERIALS | MERCK PATENT GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| US-11832513-B2 | Materials for electronic devices | MERCK PATENT GMBH (DE) | 2023-11-28 | — | — | US | disclosed |
| US-11832513-B2 | Materials for electronic devices | MERCK PATENT GMBH (DE) | 2023-11-28 | — | — | US | disclosed |
| US-20230373941-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0184384-B1 | SUBSTITUTED DIHYDROQUINOLONE CARBOXYLIC ACIDS, ANTI-BACTERIAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1989-08-02 | — | — | EP | disclosed |
| US-4623650-A | BACTERICIDES | PFIZER INC. (US) | 1986-11-18 | — | — | US | disclosed |
| EP-0184384-A1 | Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them | PFIZER INC. (US) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11832513-B2 | Materials for electronic devices | PNMT, DDT, COMT | L3MBTL1 3148/4885NPC1 1893/4885RAB9A 1917/4885 |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | L3MBTL1 1792/4885NPC1 827/4885RAB9A 3277/4885 |
| US-20230373941-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | CYP2E1, GPX1, ERCC1 | L3MBTL1 3395/4885NPC1 2104/4885RAB9A 1437/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | L3MBTL1 2721/4885NPC1 790/4885RAB9A 1615/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | L3MBTL1 2818/4885NPC1 804/4885RAB9A 1619/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | L3MBTL1 2721/4885NPC1 790/4885RAB9A 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.